Mobile Navigation

Subscribe for the Newsletter

Community

Cynthia A. Challener, Ph.D.
Cynthia A. Challener, Ph.D.

Scientific Content Director, Pharma's Almanac

Dr. Challener is an established industry editor and technical writing expert in the areas of chemistry and pharmaceuticals. She writes for various corporations and associations, as well as marketing agencies and research organizations, including That’s Nice and Nice Insight.
275 Contributions1 / 14
Optimizing Plasmid Production to Meet Growing Demand
Plasmid Manufacturing

Optimizing Plasmid Production to Meet Growing Demand

Cynthia A. Challener, Ph.D.; Danielle Alvarez

Pharma's Almanac

PAO-04-23-NI-01Apr 03, 2023
Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down
FDA New Drug Approvals

Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-23-NI-03Mar 07, 2023
The Opportunities and Challenges Posed by Biosimilar Interchangeability
Interchangeable Biosimilars

The Opportunities and Challenges Posed by Biosimilar Interchangeability

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-23-NI-01Mar 07, 2023
Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles
Cell Therapy

Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-01-23-NI-01Jan 31, 2023
Synthetic Biology: A Potential Game-Changer for the Biopharma Industry
Synthetic Biology

Synthetic Biology: A Potential Game-Changer for the Biopharma Industry

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-12-022-NI-01Dec 23, 2022
Revisiting Comparative Drug Development
One Medicine

Revisiting Comparative Drug Development

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-11-022-NI-11Nov 18, 2022
The Exciting Potential of Inhalation Vaccines
Inhalation Vaccines

The Exciting Potential of Inhalation Vaccines

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-11-022-NI-10Nov 15, 2022
Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality
Cell Therapy

Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-022-NI-08Nov 15, 2022
Optimizing Transient Transfection for Viral Vector Production
Viral Vector Manufacturing

Optimizing Transient Transfection for Viral Vector Production

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-022-NI-09Nov 15, 2022
Potential Applications for Antisense Oligonucleotide Therapies Continue to Expand
Column: New Drug Watch

Potential Applications for Antisense Oligonucleotide Therapies Continue to Expand

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-10-022-NI-06Oct 11, 2022
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
mRNA

Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-10-022-NI-02Oct 11, 2022
Leveraging Big Data, Artificial Intelligence, and Machine Learning for Drug Discovery, Development, Manufacturing, and More
Big Data

Leveraging Big Data, Artificial Intelligence, and Machine Learning for Drug Discovery, Development, Manufacturing, and More

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-022-NI-05Oct 11, 2022
Taking Adoptive Cell Therapies to the Next Level
Cell Therapy

Taking Adoptive Cell Therapies to the Next Level

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-06-022--NI-04Jun 24, 2022
Quantum Computing will Transform Drug Discovery, Development, Manufacturing, and Supply Chain Management
Quantum Computing

Quantum Computing will Transform Drug Discovery, Development, Manufacturing, and Supply Chain Management

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-06-022--NI-10Jun 24, 2022
Alzheimer Drug Still Controversial
Column: New Drug Watch

Alzheimer Drug Still Controversial

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-022-NI-04Mar 23, 2022
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Column: Technology

mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez

Pharma's Almanac

PAO-03-022-NI-02Mar 23, 2022
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
COVID-19 Vaccines

Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-022-NI-05Mar 18, 2022
The Evolution and the Future of Pharma
Pharma's Almanac

The Evolution and the Future of Pharma

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-22-R250-07Mar 08, 2022
Working to Overcome Analytical Challenges Posed by Genetic Vaccines
Genetic Vaccines

Working to Overcome Analytical Challenges Posed by Genetic Vaccines

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-06-21-NI-01Jun 04, 2021
A Look at Genetic Vaccine Development and Manufacturing
Vaccines

A Look at Genetic Vaccine Development and Manufacturing

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-05-21-NI-03May 17, 2021
1 / 14